Page 344 Acute Pain Management
P. 344




prehospital
environment,
but
this
is
not
encouraged
because
of
the
unpredictable
impact

upon
the
pharmacokinetics
in
a
poorly
perfused
patient.

Both
morphine
and
fentanyl
are
commonly
used
for
prehospital
analgesia.
Morphine
(Bruns
et

al,
1992
Level
IV;
Fullerton‐Gleason
et
al,
2002
Level
IV)
and
fentanyl
(Kanowitz
et
al,
2006
Level
IV),

as
well
as
tramadol
(Ward
et
al,
1997
Level
IV)
have
been
shown
to
provide
effective
and
safe

pain
relief
in
patients
being
transported
by
road.
Fentanyl
was
also
safe
and
effective
when

given
to
patients
during
helicopter
transfers
(Thomas
et
al,
2005
Level
IV;
Krauss
et
al,
2009

Level
IV).

Morphine
doses
of
0.1
mg/kg
IV
followed
by
0.05
mg/kg
every
5
mins
as
needed
provided

more
rapid
pain
relief
and
patient
satisfaction
than
doses
that
were
50%
lower
(Bounes
et
al,

2008
Level
II).

In
a
comparison
of
IV
fentanyl
and
morphine
bolus
doses
given
every
5
minutes
as
needed

for
prehospital
analgesia,
no
difference
was
found
in
pain
relief
or
incidence
of
side
effects

(Galinski
et
al,
2005
Level
II).
Similarly,
there
was
no
difference
in
pain
relief
or
adverse
effects

reported
in
a
comparison
of
IV
tramadol
and
morphine
(Vergnion
et
al,
2001
Level
II).

When
used
to
treat
acute
cardiac
chest
pain
during
prehospital
transfer,
IV
alfentanil
provided

more
rapid
relief
than
IV
morphine
(Silfvast
&
Saarnivaara,
2001
Level
II).
IN
fentanyl
and

IV
morphine
were
equally
effective
for
patients
with
cardiac
and
non‐cardiac
acute
pain

(Rickard
et
al,
2007
Level
II).

A
comparison
of
5
mg
and
10
mg
nalbuphine
doses
given
IV
and
repeated
at
3‐minute

intervals
to
a
total
of
20
mg,
showed
that
use
of
the
larger
dose
led
to
better
pain
relief
but

higher
patient‐reported
drowsiness;
over
half
the
patients
in
both
groups
still
had
significant

pain
on
arrival
at
the
hospital
(Woollard
et
al,
2004
Level
II).


Inhalational agents
Inhalational
analgesics
can
provide
early
pain
relief
in
the
prehospital
environment
and
are

used
before
opioids
in
many
situations.
However,
variations
in
the
availability
of
different

agents
have
a
marked
impact
on
regional
practices.
In
one
series,
patients
with
extremity

fractures
were
more
likely
to
receive
N 2O
than
morphine
(White
et
al,
2000),
whereas
in

another
series
N 2O
was
not
used
(Rogovik
&
Goldman,
2007).
Methoxyflurane
is
not
available
in

CHAPTER
9
 many
countries,
but
in
Australia
it
has
replaced
N 2O
in
most
prehospital
settings.
Provision
of

N 2O
in
ambulances
is
hampered
by
difficulties
providing
a
scavenger
system
that
minimises

occupational
exposure
and
the
bulk/logistical
issues
associated
with
managing
cylinders
of

oxygen
and
nitrous
oxide
(Entonox®
cylinders
are
a
mixture
of
50%
N 2O
and
50%
oxygen)
that

separate
at
low
temperatures.
The
demand
valves
are
costly
and
require
maintenance,
and

the
inability
to
activate
the
valve
and
effectively
use
Entonox®
equipment
has
been
rated
as
a

major
factor
limiting
use
in
children
under
5
year
(Watkins,
2006).
There
have
been
no
RCTs
of

methoxyflurane
(Grindlay
&
Babl,
2009)
or
N 2O
(Faddy
&
Garlick,
2005),
and
no
large
case
series

comparing
efficacy
with
other
analgesic
agents
in
the
prehospital
setting.


Methoxyflurane
reduced
pain
scores
(mean
2.47±0.24
on
NRS
0
to
10)
in
adults,
the
majority

of
whom
had
musculoskeletal
pain.
The
incidence
of
nausea
was
8%,
and
11%
had
increased

drowsiness
(Buntine
et
al,
2007
Level
IV).
When
graded
by
the
paramedic,
methoxyflurane
also

reduced
pain
scores
in
children
(Babl
et
al,
2006
Level
IV).
The
overall
incidence
of
drowsiness

was
27%,
but
the
risk
of
deep
sedation
was
significantly
higher
in
younger
children.
In
both
of

these
studies,
methoxyflurane
was
delivered
by
a
Penthrox®
inhaler
which
contains
3
mL
of

methoxyflurane
and
lasts
for
25
to
30
minutes
(Medical
Developments
International,
2001).
There

have
been
no
reports
of
toxicity
with
analgesic
use
if
doses
are
limited
to
3
mL
repeated
once

with
a
maximum
of
15
mL
per
week,
or
a
maximum
of
0.5%
for
one
hour
(Grindlay
&
Babl,
2009)

(see
also
Section
4.3.1).

296
 Acute
Pain
Management:
Scientific
Evidence

   339   340   341   342   343   344   345   346   347   348   349